vs
Side-by-side financial comparison of Hologic (HOLX) and LANDSTAR SYSTEM INC (LSTR). Click either name above to swap in a different company.
LANDSTAR SYSTEM INC is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.1× Hologic). Hologic runs the higher net margin — 17.1% vs 3.4%, a 13.7% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 1.6%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -2.2%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Landstar System, Inc. is an American transportation services company specializing in logistics and, more specifically, third-party logistics. Landstar utilizes an extensive network of over 8,800 independent owner-operators, referred to internally as business capacity owners (BCOs), over 1,000 independent freight agents, and over 70,000 vetted carriers. Landstar provides services principally throughout the United States and to a lesser extent in Canada and between the U.S. and Canada, Mexico, ...
HOLX vs LSTR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.2B |
| Net Profit | $179.1M | $39.4M |
| Gross Margin | 56.0% | 9.6% |
| Operating Margin | 22.6% | 4.5% |
| Net Margin | 17.1% | 3.4% |
| Revenue YoY | 2.5% | 1.6% |
| Net Profit YoY | -10.9% | 32.3% |
| EPS (diluted) | $0.79 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $988.0M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B |
| Q1 26 | — | $39.4M | ||
| Q4 25 | $179.1M | $23.9M | ||
| Q3 25 | $187.2M | $19.4M | ||
| Q2 25 | $194.9M | $41.9M | ||
| Q1 25 | $-17.4M | $29.8M | ||
| Q4 24 | $201.0M | $46.2M | ||
| Q3 24 | $178.6M | $50.0M | ||
| Q2 24 | $194.5M | $52.6M |
| Q1 26 | — | 9.6% | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
| Q1 26 | — | 4.5% | ||
| Q4 25 | 22.6% | 2.5% | ||
| Q3 25 | 22.6% | 2.2% | ||
| Q2 25 | 24.9% | 4.6% | ||
| Q1 25 | -0.7% | 3.4% | ||
| Q4 24 | 22.5% | 4.8% | ||
| Q3 24 | 23.3% | 5.2% | ||
| Q2 24 | 24.1% | 5.6% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | 17.1% | 2.0% | ||
| Q3 25 | 17.8% | 1.6% | ||
| Q2 25 | 19.0% | 3.5% | ||
| Q1 25 | -1.7% | 2.6% | ||
| Q4 24 | 19.7% | 3.8% | ||
| Q3 24 | 18.1% | 4.1% | ||
| Q2 24 | 19.2% | 4.3% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $0.79 | $0.70 | ||
| Q3 25 | $0.84 | $0.56 | ||
| Q2 25 | $0.86 | $1.20 | ||
| Q1 25 | $-0.08 | $0.85 | ||
| Q4 24 | $0.87 | $1.30 | ||
| Q3 24 | $0.75 | $1.41 | ||
| Q2 24 | $0.82 | $1.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $411.0M |
| Total DebtLower is stronger | $2.5B | $26.1M |
| Stockholders' EquityBook value | $5.2B | $799.0M |
| Total Assets | $9.2B | $1.6B |
| Debt / EquityLower = less leverage | 0.48× | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $411.0M | ||
| Q4 25 | $2.4B | $452.2M | ||
| Q3 25 | $2.2B | $434.4M | ||
| Q2 25 | $1.9B | $426.2M | ||
| Q1 25 | $1.6B | $473.4M | ||
| Q4 24 | $2.0B | $566.6M | ||
| Q3 24 | $2.3B | $531.3M | ||
| Q2 24 | $2.4B | $504.0M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | $2.5B | $0 | ||
| Q3 25 | $2.5B | $0 | ||
| Q2 25 | $2.5B | $0 | ||
| Q1 25 | $2.5B | $0 | ||
| Q4 24 | $2.5B | $0 | ||
| Q3 24 | $2.5B | $0 | ||
| Q2 24 | $2.5B | $0 |
| Q1 26 | — | $799.0M | ||
| Q4 25 | $5.2B | $795.7M | ||
| Q3 25 | $5.0B | $888.7M | ||
| Q2 25 | $4.8B | $921.8M | ||
| Q1 25 | $4.6B | $930.8M | ||
| Q4 24 | $4.8B | $972.4M | ||
| Q3 24 | $5.1B | $1.0B | ||
| Q2 24 | $5.0B | $1.0B |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $9.2B | $1.6B | ||
| Q3 25 | $9.0B | $1.7B | ||
| Q2 25 | $8.8B | $1.7B | ||
| Q1 25 | $8.5B | $1.7B | ||
| Q4 24 | $8.7B | $1.8B | ||
| Q3 24 | $9.2B | $1.8B | ||
| Q2 24 | $8.9B | $1.8B |
| Q1 26 | — | 0.03× | ||
| Q4 25 | 0.48× | 0.00× | ||
| Q3 25 | 0.50× | 0.00× | ||
| Q2 25 | 0.52× | 0.00× | ||
| Q1 25 | 0.55× | 0.00× | ||
| Q4 24 | 0.53× | 0.00× | ||
| Q3 24 | 0.49× | 0.00× | ||
| Q2 24 | 0.51× | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $72.7M | ||
| Q3 25 | $355.1M | $89.3M | ||
| Q2 25 | $343.3M | $7.1M | ||
| Q1 25 | $169.4M | $55.7M | ||
| Q4 24 | $189.3M | $61.1M | ||
| Q3 24 | $367.0M | $83.1M | ||
| Q2 24 | $405.8M | $48.1M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $70.5M | ||
| Q3 25 | $341.4M | $86.0M | ||
| Q2 25 | $330.5M | $4.7M | ||
| Q1 25 | $153.9M | $53.8M | ||
| Q4 24 | $172.5M | $54.4M | ||
| Q3 24 | $350.6M | $75.6M | ||
| Q2 24 | $385.3M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 6.0% | ||
| Q3 25 | 32.5% | 7.1% | ||
| Q2 25 | 32.3% | 0.4% | ||
| Q1 25 | 15.3% | 4.7% | ||
| Q4 24 | 16.9% | 4.5% | ||
| Q3 24 | 35.5% | 6.2% | ||
| Q2 24 | 38.1% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 0.2% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 1.3% | 0.2% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.6% | 0.6% | ||
| Q3 24 | 1.7% | 0.6% | ||
| Q2 24 | 2.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 3.04× | ||
| Q3 25 | 1.90× | 4.61× | ||
| Q2 25 | 1.76× | 0.17× | ||
| Q1 25 | — | 1.87× | ||
| Q4 24 | 0.94× | 1.32× | ||
| Q3 24 | 2.05× | 1.66× | ||
| Q2 24 | 2.09× | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LSTR
Segment breakdown not available.
